Skip to main content
S 296 112th Congress Senate

Preserving Access to Life-Saving Medications Act

Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to provide the Food and Drug Administration with improved capacity to prevent drug shortages.

Introduced: March 9, 2011 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Health Business recordsDrug safety, medical device, and laboratory regulationGovernment information and archivesManufacturingPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 112th Congress ended
It never became law before the 112th Congress (2011–2012) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 7, 2011
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 7, 2011
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 7, 2011

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

Preserving Access to Life-Saving Medications Act - Amends the Federal Food, Drug, and Cosmetic Act to require a prescription drug manufacturer to notify the Secretary of Health and Human Services (HHS) of a discontinuance, interruption, or other adjustment of the manufacture of the drug that would likely result in a shortage of such drug. Requires: (1) six months notice of any discontinuance or planned interruption or adjustment, and (2) notice as soon as practicable after becoming aware of such interruption or adjustment in the case of any other interruption or adjustment. Applies this Act to any approved prescription drug that is not a product that was originally derived from human tissue and was replaced by a recombinant product.

Sets forth the types of adjustment for which a manufacturer must submit notice, including: (1) adjustments related to the supply of raw materials, (2) adjustments to production capabilities, (3) business decisions that may affect the manufacture of the drug, and (4) other adjustments as determined appropriate by the Secretary.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 12
All 12 Democratic 10 Republican 1 Independent 1
D
Durbin, Richard J.
Illinois · Feb 27, 2012
 I
Sanders, Bernard
Vermont · Feb 15, 2012
 D
Warner, Mark R.
Virginia · Jan 30, 2012
 D
Shaheen, Jeanne
New Hampshire · Jan 23, 2012
 D
Cantwell, Maria
Washington · Nov 15, 2011
 D
Merkley, Jeff
Oregon · Nov 2, 2011
 D
Gillibrand, Kirsten E.
New York · Oct 11, 2011
 R
Collins, Susan M.
Maine · Sep 6, 2011
 D
Reed, Jack
Rhode Island · Jun 29, 2011
 D
Coons, Christopher A.
Delaware · May 16, 2011
 D
Schumer, Charles E.
New York · May 9, 2011
 D
Blumenthal, Richard
Connecticut · Mar 9, 2011
Cite this page click to expand
APA
U.S. Congress. (2026). S. 296: Preserving Access to Life-Saving Medications Act. 112th Congress. Open America. https://openamerica.io/bill/112-S-296/
MLA
"S. 296: Preserving Access to Life-Saving Medications Act." 112th Congress, 2026, Open America, https://openamerica.io/bill/112-S-296/.
Bluebook (legal)
S. 296, 112th Cong. (2026), https://openamerica.io/bill/112-S-296/.
Markdown link
[S. 296: Preserving Access to Life-Saving Medications Act](https://openamerica.io/bill/112-S-296/)
Report a problem